1. Home
  2. EARN vs BIOA Comparison

EARN vs BIOA Comparison

Compare EARN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.36

Market Cap

189.7M

Sector

Real Estate

ML Signal

HOLD

Logo BioAge Labs Inc. Common Stock

BIOA

BioAge Labs Inc. Common Stock

HOLD

Current Price

$11.61

Market Cap

175.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
BIOA
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
175.7M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
EARN
BIOA
Price
$5.36
$11.61
Analyst Decision
Buy
Hold
Analyst Count
2
4
Target Price
$5.88
$9.00
AVG Volume (30 Days)
292.9K
297.0K
Earning Date
11-19-2025
11-06-2025
Dividend Yield
17.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
$5,917,000.00
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$2.88
52 Week High
$6.99
$20.37

Technical Indicators

Market Signals
Indicator
EARN
BIOA
Relative Strength Index (RSI) 54.26 78.27
Support Level $5.25 $8.46
Resistance Level $5.55 $9.62
Average True Range (ATR) 0.10 0.58
MACD 0.01 0.17
Stochastic Oscillator 59.57 97.30

Price Performance

Historical Comparison
EARN
BIOA

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About BIOA BioAge Labs Inc. Common Stock

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Share on Social Networks: